Description

Tesamorelin Research Topics:

1. Reduction of Visceral Fat:

   Tesamorelin significantly decreases visceral adipose tissue (VAT), particularly in individuals with HIV-associated lipodystrophy. This reduction in VAT is accompanied by improvements in lipid profiles, such as decreased triglyceride levels and improved cholesterol ratios (PMID: 28832410).

2. Metabolic Improvements:

   The peptide enhances insulin sensitivity and lowers fasting glucose levels, contributing to better metabolic control, especially in individuals with type 2 diabetes (PMID: 28617838).

3. Cognitive Function and Quality of Life:

   Research indicates potential benefits in cognitive function and quality of life, although these areas require further investigation (PMID: 22869065).

Peer Reviewed Studies 

• Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation

Falutz, J., Allas, S., Mamputu, J. C., Potvin, D., Kotler, D., Somero, M., … & Grinspoon, S. (2008)

Aids, 22(14), 1719-1728.

• Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy

Spooner, L. M., & Olin, J. L. (2012)

Annals of Pharmacotherapy, 46(2), 240-247

Structure